1-2 of 2
Sai Li, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-137388
Published: 2020
Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS
Journal: Blood
Blood (2014) 124 (21): 1995.
https://doi.org/10.1182/blood.V124.21.1995.1995
Published: 2014